Effects of cigarette smoking and cytochrome P450 2D6 genotype on fluvoxamine concentration in plasma of Japanese patients

Biological and Pharmaceutical Bulletin

Volumn 33, Issue 2, 2010, Pages 285-288

  Katoh, Yasuhiro ^a   Uchida, Shinya ^a   Kawai, Masayoshi ^b   Takei, Noriyoshi ^b   Mori, Norio ^b   Kawakami, Junichi ^b   Kagawa, Yoshiyuki ^a   Yamada, Shizuo ^a   Namiki, Noriyuki ^a   Hashimoto, Hisakuni ^c  

^a UNIVERSITY OF SHIZUOKA   (Japan)

^b HAMAMATSU UNIVERSITY SCHOOL OF MEDICINE   (Japan)

^c NIHON PHARMACEUTICAL UNIVERSITY   (Japan)

Author keywords

Cigarette smoking; Cytochrome P450 1A2; Cytochrome P450 2D6; Fluvoxamine; Genetic polymorphism

Indexed keywords

CYTOCHROME P450 1A2; CYTOCHROME P450 2D6; FLUVOXAMINE; FLUVOXAMINE MALEATE;

ADULT; AGED; ALLELE; ARTICLE; CIGARETTE SMOKING; CLINICAL ARTICLE; CONTROLLED STUDY; DOSE RESPONSE; DRUG BLOOD LEVEL; DRUG EFFECT; DRUG METABOLISM; FEMALE; GENE MUTATION; GENOTYPE; HUMAN; JAPANESE; MALE; STEADY STATE; TREATMENT DURATION;

ADULT; AGED; ASIAN CONTINENTAL ANCESTRY GROUP; CYTOCHROME P-450 CYP2D6; FEMALE; FLUVOXAMINE; GENOTYPE; HUMANS; MALE; MIDDLE AGED; SMOKING; YOUNG ADULT;

EID: 76049087825     PISSN: 09186158     EISSN: 13475215     Source Type: Journal    
DOI: 10.1248/bpb.33.285     Document Type: Article

References (23)

1. Wilde M. I., Plosker G. L., Benfield P., Drugs, 46, 895-924 (1993).
2. Perucca E., Gatti G., Spina E., Clin. Pharmacokinet., 27, 175-190 (1994).
3. Miura M., Ohkubo T., Xenobiotica, 37, 169-179 (2007).
4. Linnet K., Wiborg O., Clin. Pharmacol. Ther., 60, 41-47 (1996).
5. Dahl M. L., Bertilsson L., Nordin C., Psychopharmacology, 123, 315-319 (1996).
6. Gaedigk A., Blum M., Gaedigk R., Eichelbaum M., Meyer U. A., Am. J. Hum. Genet., 48, 943-950 (1991).
7. Ingelman-Sundberg M., Pharmacogenomics J., 5, 6-13 (2005).
8. Sakuyama K., Sasaki T., Ujiie S., Obata K., Mizugaki M., Ishikawa M., Hiratsuka M., Drug Metab. Dispos., 36, 2460-2467 (2008).
9. Carrillo J. A., Dahl M. L., Svensson J. O., Alm C., Rodríguez I., Bertilsson L., Clin. Pharmacol. Ther., 60, 183-190 (1996).
10. Watanabe J., Suzuki Y., Fukui N., Sugai T., Ono S., Inoue Y., Someya T., Ther. Drug Monit., 30, 705-708 (2008).
11. Gerstenberg G., Aoshima T., Fukasawa T., Yoshida K., Takahashi H., Higuchi H., Murata Y., Shimoyama R., Ohkubo T., Shimizu T., Otani K., Ther. Drug Monit., 25, 463-468 (2003).
12. Ohara K., Tanabu S., Ishibashi K., Ikemoto K., Yoshida K., Shibuya H., Eur. J. Clin. Pharmacol., 58, 659-661 (2003).
13. Hunt S. N., Jusko W. J., Yurchak A. M., Clin. Pharmacol. Ther., 19, 546-551 (1976).
14. Grygiel J. J., Birkett D. J., Clin. Pharmacol. Ther., 30, 491-496 (1981).
15. Nakajima M., Yokoi T., Mizutani M., Shin S., Kadlubar F. F., Kamataki T., Cancer Epidemiol. Biomarkers Prev., 3, 413-421 (1994).
16. Perel J. M., Mendlewicz J., Shostak M., Kantor S. J., Glassman A. H., Neuropsychobiology, 2, 193-202 (1976).
17. Spigset O., Carleborg L., Hedenmalm K., Dahlqvist R., Clin. Pharmacol. Ther., 58, 399-403 (1995).
18. Nakajima M., Yokoi T., Mizutani M., Kinoshita M., Funayama M., Kamataki T., J. Biochem. (Tokyo), 125, 803-808 (1999).
19. Kubota T., Yamaura Y., Ohkawa N., Hara H., Chiba K., Br. J. Clin. Pharmacol., 50, 31-34 (2000).
20. Sproule B. A., Naranjo C. A., Brenmer K. E., Hassan P. C., Clin. Pharmacokinet., 33, 454-471 (1997).
21. Sugahara H., Maebara C., Ohtani H., Handa M., Ando K., Mine K., Kubo C., Ieiri I., Sawada Y., Eur. J. Clin. Pharmacol., 65, 699-704 (2009).
22. Fukui N., Suzuki Y., Sawamura K., Sugai T., Watanabe J., Inoue Y., Someya. T., Ther. Drug Monit., 29, 185-189 (2007).
23. Soyama A., Saito Y., Hanioka N., Maekawa K., Komamura K., Kamakura S., Kitakaze M., Tomoike H., Ueno K., Goto Y., Kimura H., Katoh M., Sugai K., Saitoh O., Kawai M., Ohnuma T., Ohtsuki T., Suzuki C., Minami N., Kamatani N., Ozawa S., Sawada J., Drug Metab. Pharmacokinet., 20, 24-33 (2005).